Vanderbilt Eye Institute researchers have discovered that an imbalance in the ionic environment of retinal ganglion cells may contribute to functional impairments in glaucoma.
Increasing a certain signaling molecule prevents the degeneration of retinal cells that are lost in glaucoma, suggesting a new way to treat this disease.
A signaling molecule called interleukin-6 may be a therapeutic target to prevent vision loss or nerve degeneration in glaucoma, Vanderbilt researchers have discovered.
Accessibility Tools